Kailera debuts Q1 2026: $79M loss, $582M cash, IPO adds $719M runway into mid-2028

Filed May 26, 2026 · Period ending March 31, 2026 · ~2 min read

Key Changes

• high

  Clinical-stage obesity biotech reports $78.9M Q1 2026 net loss (vs $18.0M Q1 2025), driven by $70.9M R&D spend ramping Phase 3 trials for lead candidate ribupatide injection. No revenue generated; accumulated deficit reaches $447.5M.

  MD&A: Financial Position verify on EDGAR →
• high

  Company holds $581.9M cash as of March 31, 2026, plus $718.8M gross IPO proceeds raised in April 2026. Management projects runway into mid-2028, after which substantial additional funding will be required to continue operations.

  MD&A: Liquidity verify on EDGAR →
• high

  Positive Phase 3 data for oral candidate KAI-7535 in type 2 diabetes (HbA1c reduction 1.40-1.68% at Week 32) and Phase 1 tri-agonist data (16.0% mean weight loss at Week 12) reported May 2026. Obesity trial data for KAI-7535 expected later in 2026.

  MD&A: Clinical Results verify on EDGAR →